Ocrelizumab

Drug Profile

Ocrelizumab

Alternative Names: 2nd Generation Anti-CD20; Anti-CD20 monoclonal antibody - Biogen; Humanised Anti-CD20 mAb; OCR; Ocrevus; PRO 70769; R 1594; RG 1594; rhuMab 2H7; RO4964913

Latest Information Update: 25 Jan 2017

Price : $50

At a glance

  • Originator Biogen Idec; Genentech
  • Developer Biogen; Biogen Idec; Chugai Pharmaceutical; Genentech; Roche
  • Class Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Multiple sclerosis
  • Suspended Systemic lupus erythematosus
  • Discontinued Eye disorders; Haematological malignancies; Lupus nephritis; Rheumatoid arthritis

Most Recent Events

  • 18 Jan 2017 University at Buffalo plans a phase IV trial for Multiple sclerosis in USA (IV) (NCT03025269)
  • 22 Dec 2016 Efficacy and adverse events data from OPERA I and OPERA II studies in Multiple sclerosis released by Genentech
  • 20 Dec 2016 PDUFA action date extended by US FDA to 28/03/2017 for BLA for Multiple sclerosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top